成纤维细胞生长因子研究进展

成纤维细胞生长因子8(fibroblast growth factor 8,FGF8)是成纤维细胞生长因子家族的成员之一,是动物组织器官发育过程中重要的分泌性调控因子.在胚胎发育的早期,FGF8广泛表达.它可以介导胚胎期的上皮和间充质的转化,在原肠的形成,早期器官如前后脑、咽、心脏、生殖器官和指等的形成和分化中都起到关键性的作用.本文就FGF8在器官发育中的作用及其研究进行概述.     

碱性成纤维细胞生长因子对培养的瘢痕成纤维细胞FN合成的调控作用

目的探讨碱性成纤维细胞生长因子（bFGF）对成纤维细胞纤维连结蛋白（FN）合成的调控作用。方法采用细胞培养、ELISA法、RT-PCR方法观察bFGF在不同剂量下对瘢痕来源的成纤维细胞FN合成的影响。结果FN的表达在低bFGF浓度组与对照组无明显差异,随着浓度的升高表现为增高趋势,以50、100、500ng／ml最显著,与对照组之间有显著性差异（P〈0．05）。FN mRNA表达在50-100ng／ml组明显升高,与对照组间有显著性差异（P〈0．05）。mRNA表达趋势与上清中蛋白的表达具有一致性。结论高浓度bFGF刺激FN合成可能是bFGF促进创面愈合的重要原因。     

成纤维细胞生长因子研究进展

成纤维细胞生长因子（ＦＧＦ）家族至少有七个成员,有些成员是原癌基因的产物。它们对多种细胞的生长与分化具有调节作用。该家族存在两类受体,高亲和力受体具有酷氨酸蛋白激酶活性,低亲和力受体为肝素受体。ＦＧＦ对神经生长因子、血小板衍生生长因子的表达有一定调控作用。     

成纤维细胞生长因子的研究

成纤维细胞生长因子的研究崔亚东（阜阳师范学院生物系,安徽阜阳２３６０３２）关键词成纤维细胞生长因子早在１９４０年,人们发现脑和垂体提取液中含有一种能促进成纤维细胞生长的活性物质。直到１９７４年,该物质才被分离纯化,命名为成纤维细胞生长因子（ＦＧＦ）。...     

成纤维细胞生长因子研究

成纤维细胞生长因子（ＦＧＦ）是广泛存在于多种组织中的一类多肽生长因子。ＦＧＦ家族至少有７个成员,有些成员是原癌基因的产物。该家族存在２类受体：高亲和力受体具有酪氨酸蛋白激酶活性;低亲和力受体为肝素样受体。它们对多种细胞的生长和分化具有调节作用。近年来研究表明,ＧＦＧ与许多疾病有关。     

碱性成纤维细胞生长因子

综述了近年来碱性纤维细胞生长因子（ｂＦＧＦ）的研究进展,重点介绍了ｂＦＧＦ的两类受体及其在信号传递过程中的作用,讨论了ｂＦＧＦ的基因结构及表达调控机制,阐述了ＢＦＧＦ的生物学功能。     

成纤维细胞生长因子23（FGF23)在终末期肾病患者继发性甲状旁腺功能 亢进中的作用

目的:探究成纤维细胞生长因子23(FGF23)在终末期肾病患者继发性甲状旁腺功能亢进中的作用机制。方法:选取我院2013年2月-2015年5月期间收治的58例终末期肾病进入血液透析的患者,所有患者均经甲状旁腺CT增强扫描,无增生及结节。按照i PTH值将其分为两组,i PTH300 pg/m L为观察组,150 pg/m L≤i PHT≤300 pg/m L为对照组,每组29例。患者均予碳酸钙以及活性维生素D3进行治疗。对患者钙、磷、白蛋白、血脂以及FGF23、i PTH、1,25(OH)_2D_3进行检验。结果:治疗后观察组患者FGF23及i PTH均高于对照组,差异具有统计学意义(P0.05)。观察组血尿素氮、血肌酐与透析前相比明显下降,对照组血尿素氮、血肌酐与透析前相比明显下降,差异有统计学意义(P0.01);1,25(OH)_2D_3以及血白蛋白水平是影响Log FGF23的独立影响因素。结论:FGF23在终末期肾病患者继发性甲状旁腺功能亢进发病中发生作用,可作用临床诊断依据。     

成纤维细胞生长因子与心血管疾病

成纤维细胞生长因子（ＦＧＦ）是广泛存在于体内多种组织中的一类多肽生长因子,主要分为ａＦＧＦ和ｂＦＧＦ两大类;由于对肝素有很强的亲和力,故又命名为肝素结合生长因子。近年研究发现,在血管内皮细胞,平滑肌细胞和心肌细胞中亦含有一定数量的ＦＧＦ。ＦＧＦ有很强的促进血管形成作用,能刺激血管内皮细胞分裂和迁移,促进平滑肌细胞增生,在创伤愈合和组织修复过程中起很重要的作用。ＦＧＦ也存在于胚胎和成年心肌细胞中,参     

碱性成纤维细胞生长因子研究进展

碱性成纤维细胞生长因子是一种在体内分布广泛、生理功能重要的生长因子,本文综合讨论了其家族成员、分子结构、生物学功能、作用机理和研究趋向等问题。     

FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness

ObjectiveTo investigate the usefulness of Fibroblast Growth Factor 23 (FGF-23) and vitamin D as possible biomarkers of pre-clinical atherosclerosis, assessed as arterial stiffness (AS), in a group of subjects with type 1 diabetes (T1DM) and no previous cardiovascular events.ResultsPatients with T1DM had higher aPWV compared with controls (p<0.001), but they did not present differences in 25(OH)D (70.3(50.4–86.2)nmol/L vs. 70.7(59.7–83.0)nmol/L; p = 0.462) and in FGF-23 plasma concentrations (70.1(38.4–151.9)RU/mL vs. 77.6(51.8–113.9)RU/mL; p = 0.329). In T1DM patients, higher concentrations of FGF-23 were positively associated with aPWV after adjusting for eGFR and classical cardiovascular risk factors (model 1: ß = 0.202, p = 0.026), other mineral metabolism parameters (model 2: ß = 0.214, p = 0.015), microvascular complications, low-grade inflammation and ED markers (model 3: ß = 0.170, p = 0.045). Lower 25(OH)D concentrations were also associated with higher aPWV after adjusting for all the above-mentioned factors (model 3: ß = -0.241, p = 0.015).ConclusionsWe conclude that both FGF-23 plasma concentrations (positively) and 25(OH)D serum concentrations (negatively) are associated with AS in patients with T1DM and no previous cardiovascular events.     

FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis

Fibroblast growth factor 23 (FGF-23) and Klotho are secretory proteins that regulate mineral-ion metabolism. Fgf-23(-/-) or Klotho(-/-) knockout mice exhibit several pathophysiological processes consistent with premature aging including severe atrophy of tissues. We show that the signal transduction pathways initiated by FGF-23-Klotho prevent tissue atrophy by stimulating proliferation and preventing apoptosis caused by excessive systemic vitamin D. Because serum levels of active vitamin D are greatly increased upon genetic ablation of Fgf-23 or Klotho, we find that these molecules have a dual role in suppression of apoptotic actions of vitamin D through both negative regulation of 1alpha-hydroxylase expression and phosphoinositide-3 kinase-dependent inhibition of caspase activity. These data provide new insights into the physiological roles of FGF-23 and Klotho.     

FGF-23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis

Abnormal blood cell production is associated with chronic kidney disease (CKD) and cardiovascular disease (CVD). Bone-derived FGF-23 (fibroblast growth factor-23) regulates phosphate homeostasis and bone mineralization. Genetic deletion of Fgf-23 in mice (Fgf-23^−/−) results in hypervitaminosis D, abnormal mineral metabolism, and reduced lymphatic organ size. Elevated FGF-23 levels are linked to CKD and greater risk of CVD, left ventricular hypertrophy, and mortality in dialysis patients. However, whether FGF-23 is involved in the regulation of erythropoiesis is unknown. Here we report that loss of FGF-23 results in increased hematopoietic stem cell frequency associated with increased erythropoiesis in peripheral blood and bone marrow in young adult mice. In particular, these hematopoietic changes are also detected in fetal livers, suggesting that they are not the result of altered bone marrow niche alone. Most importantly, administration of FGF-23 in wild-type mice results in a rapid decrease in erythropoiesis. Finally, we show that the effect of FGF-23 on erythropoiesis is independent of the high vitamin D levels in these mice. Our studies suggest a novel role for FGF-23 in erythrocyte production and differentiation and suggest that elevated FGF-23 levels contribute to the pathogenesis of anemia in patients with CKD and CVD.     

Clinical Disorders of Phosphorus Metabolism

Deranged phosphorus metabolism is commonly encountered in clinical medicine. Disturbances in phosphate intake, excretion and transcellular shift account for the abnormal serum levels. As a result of the essential role played by phosphate in intracellular metabolism, the clinical manifestations of hypophosphatemia and hyperphosphatemia are extensive. An understanding of the pathophysiology of various phosphate disorders is helpful in guiding therapeutic decisions.     

维持性腹膜透析患者血管钙化评估及血清sclerostin、FGF-23测定对血管钙化发生风险的预测价值研究

摘要 目的：评估维持性腹膜透析（PD）患者血管钙化（VC）情况,分析血清骨硬化蛋白（sclerostin）、成纤维生长因子-23（FGF-23）测定对VC发生风险的预测价值。方法：选择2018年5月~2021年6月期间我院收治的维持性PD患者103例为研究对象。收集所有患者的临床资料进行分析,观察VC情况,多因素Logistic回归分析维持性PD患者VC的危险因素。受试者工作特征曲线（ROC）分析血清sclerostin、FGF-23单独及联合测定对VC的预测价值。结果：103例维持性PD患者中有69例（66.99%）存在不同部位、不同程度的VC。根据是否出现VC进行分组,其中VC患者69例（VC组）,未出现VC患者34例（无VC组）。与无VC组患者相比,VC组年龄、合并糖尿病人数占比、血清sclerostin、FGF-23、血钙（Ca）水平明显更高,透析时间明显更长,全段甲状旁腺激素水平明显更低（P<0.05）。透析时间≥32月、年龄≥55岁、合并糖尿病、血清FGF-23≥80 pg/mL、Ca≥1.3 mmol/L、血清sclerostin≥7 ng/mL是维持性PD患者并发VC的危险因素（P＜0.05）。血清sclerostin、FGF-23的曲线下面积（AUC）（0.95CI）分别为0.783（0.691～0.858）、0.793（0.702～0.866）,有一定的预测效能,而两指标联合应用时：AUC（0.95CI）为0.867（0.786～0.926）,预测效能更高。结论：维持性PD患者VC的发生与透析时间、年龄、合并糖尿病、FGF-23、Ca、sclerostin有关,sclerostin、FGF-23联合测定对VC发生风险的预测价值较高,对于此类患者VC的评估具有辅助作用。     

妊娠期糖尿病患者血清NRG4、FGF-23、PGRN水平及其临床意义

摘要 目的：探讨妊娠期糖尿病患者血清神经调节蛋白4(NRG4)、成纤维细胞生长因子-23(FGF-23)、前颗粒体蛋白(PGRN)水平及其临床意义。方法：选择2018年4月至2019年11月我院诊治的90例妊娠期糖尿病患者作为糖尿病组,选择同期在我院进行健康体检的90名健康孕妇作为对照组。检测两组血清NRG4、FGF-23、PGRN水平,血脂指标[高密度脂蛋白（HDL）、总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白（LDL）]水平,肝功能指标[谷草转氨酶（AST）、谷丙转氨酶(ALT)]水平,血糖和胰岛素指标[空腹血糖（FPG）、空腹胰岛素(FINS)]水平,并计算抗胰岛素抵抗指数(HOMA-IR)、胰岛素敏感性指数（ISI）和胰岛?茁细胞功能指数(HOMA-β)。分析各临床指标间的关系。结果：与对照组相比,糖尿病组体质量指数（BMI）、TG、TC、FPG、FINS、HOMA-IR、NRG4、FGF-23、PGRN明显升高（P<0.05）,ISI和HOMA-β明显下降（P<0.05）。血清NRG4、FGF-23、PGRN与ISI和HOMA-β均呈负相关（P<0.05）,与BMI、TG、TC、FPG、FINS、HOMA-IR均呈正相关（P<0.05）。TG与NRG4表达联系密切（β=0.007,P<0.05）,ISI和HOMA-IR与FGF-23表达联系密切（β=-6.674、0.048,P<0.05）,FPG和TC与PGRN表达联系密切（β=22.308、0.507,P<0.05）。结论：妊娠期糖尿病患者血清NRG4、FGF-23、PGRN水平异常升高,并参与妊娠期糖尿病患者的糖脂代谢和胰岛素抵抗,检测其水平有助于评估妊娠期糖尿病的糖脂代谢异常情况。     

Genetic evidence of serum phosphate-independent functions of FGF-23 on bone

Maintenance of physiologic phosphate balance is of crucial biological importance, as it is fundamental to cellular function, energy metabolism, and skeletal mineralization. Fibroblast growth factor-23 (FGF-23) is a master regulator of phosphate homeostasis, but the molecular mechanism of such regulation is not yet completely understood. Targeted disruption of the Fgf-23 gene in mice (Fgf-23-/-) elicits hyperphosphatemia, and an increase in renal sodium/phosphate co-transporter 2a (NaPi2a) protein abundance. To elucidate the pathophysiological role of augmented renal proximal tubular expression of NaPi2a in Fgf-23-/- mice and to examine serum phosphate-independent functions of Fgf23 in bone, we generated a new mouse line deficient in both Fgf-23 and NaPi2a genes, and determined the effect of genomic ablation of NaPi2a from Fgf-23-/- mice on phosphate homeostasis and skeletal mineralization. Fgf-23-/-/NaPi2a-/- double mutant mice are viable and exhibit normal physical activities when compared to Fgf-23-/- animals. Biochemical analyses show that ablation of NaPi2a from Fgf-23-/- mice reversed hyperphosphatemia to hypophosphatemia by 6 weeks of age. Surprisingly, despite the complete reversal of serum phosphate levels in Fgf-23-/-/NaPi2a-/-, their skeletal phenotype still resembles the one of Fgf23-/- animals. The results of this study provide the first genetic evidence of an in vivo pathologic role of NaPi2a in regulating abnormal phosphate homeostasis in Fgf-23-/- mice by deletion of both NaPi2a and Fgf-23 genes in the same animal. The persistence of the skeletal anomalies in double mutants suggests that Fgf-23 affects bone mineralization independently of systemic phosphate homeostasis. Finally, our data support (1) that regulation of phosphate homeostasis is a systemic effect of Fgf-23, while (2) skeletal mineralization and chondrocyte differentiation appear to be effects of Fgf-23 that are independent of phosphate homeostasis.